用于治疗日光性雀斑的宽带光（BBL® HERO）与非剥脱性1,927纳米（MOXI）激光的新型联合疗法
A Novel Combination of BroadBand Light (BBL® HERO) and Nonablative Fractionated 1,927nm (MOXI) Laser for Addressing Solar Lentigines.
作者信息
Hennessey Erin
机构信息
Ms. Hennessey is the Owner of Blush Aesthetics in Perrysburg and Toledo, Ohio, and Assistant Professor, Nursing, Gonzaga University in Spokane, Washington.
出版信息
J Clin Aesthet Dermatol. 2024 Sep-Oct;17(9-10 Suppl 1):S36-S39.
Solar lentigo is a common condition that can affect people of all ages and ethnicities. The effectiveness of combining laser and light-based modalities for reducing solar lentigines was evaluated. Patients received treatment for facial solar lentigines with an advanced pulsed light device (BBL® HERO) followed by nonablative fractionated 1,927nm laser (MOXI) in a single session. Nonmalignant solar lentigines were evaluated through assessment of photographs and VISIA scans taken before and after treatment. Nine patients aged 29 to 64 years were included in this report. Across all nine patients, there was a significant increase in percentile for brown spots on VISIA scans post-treatment. Follow-up time was variable; in one patient, a marked reduction in hyperpigmentation was observed almost 20 months post-treatment. The results presented in this report demonstrate that combining BBL HERO and MOXI is effective for reducing solar lentigines.
日光性雀斑是一种常见病症，可影响所有年龄和种族的人群。评估了联合使用激光和光基治疗方式减少日光性雀斑的效果。患者在单次治疗中先用先进的脉冲光设备（BBL® HERO）对面部日光性雀斑进行治疗，随后使用非剥脱性分次1927纳米激光（MOXI）。通过评估治疗前后拍摄的照片和VISIA扫描来评估非恶性日光性雀斑。本报告纳入了9名年龄在29至64岁之间的患者。在所有9名患者中，治疗后VISIA扫描上褐色斑点的百分位数显著增加。随访时间各不相同；在一名患者中，治疗后近20个月观察到色素沉着明显减轻。本报告中的结果表明，联合使用BBL HERO和MOXI对减少日光性雀斑有效。
Zotero 插件